
Theratechnologies
- Industry Drug Manufacturers - Specialty & Generic
- Sector Healthcare
- Market Cap
- Earnings
About
Profile
Headquarters
Intraday
High
-
Low
-
52-week
High
-
Low
-
THTX
...
Available for logged in users only.
The multiple price alert feature will smartly add or remove $1 if your alert was hit.
It's only available if you are logged in, a V.I.P. member or if you are using the AI chrome extension.
Contact us via Twitter if you are interested in trying it out.
- Theratechnologies reports Q3 results
- Theratechnologies completes 1-for-4 reverse stock split
- Theratechnologies amends credit facility terms to lower minimum liquidity
- Theratechnologies announces 1-for-4 reverse stock split
- Theratechnologies reports Q2 results
- Theratechnologies GAAP EPS of -$0.11 misses by $0.06, revenue of $19.9M misses by $1.3M
- Nasdaq notifies Theratechnologies regarding share price noncompliance
- Theratechnologies reports Q4 earnings miss; initiates FY23 outlook
- Theratechnologies slumps 30% as cancer drug trial enrollment paused on efficacy, safety woes
- Theratechnologies reports Q3 results, FY22 guidance on track
- Theratechnologies stock rises 9% on positive data from early-stage trial data of cancer therapy
- Theratechnologies revenue of $19.27M misses by $0.86M, tightens FY2022 revenue outlook
- Theratechnologies stock gains on securing $100M term loan
- Theratechnologies begin enrollment in early-stage study of TH1902 in advanced cancers
- Theratechnologies reports Q1 results
- Theratechnologies GAAP EPS of -$0.34 misses by $0.26, revenue of $18.75M misses by $1.73M
- Theratechnologies net loss widens in Q3
- Theratechnologies EPS misses by $0.03, misses on revenue
- Theratechnologies reports positive results for Trogarzo IV push administration study
- Theratechnologies EPS in-line, misses on revenue